Ontak gains full US approval for CD25-positive cutaneous T-cell lymphoma
This article was originally published in Scrip
Executive Summary
Eisaihas received full US FDAapproval for its fusion protein Ontak (denileukin diftitox) for the orphan indication of persistent or recurrent CD25-positive cutaneous T-cell lymphoma (CTCL), following a Phase III trial which confirmed response rate benefits in such patients.